Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

Stock Information for Cardlytics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardlytics Inc.

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
23andMe Provides Update Regarding Court-Supervised Sale Process
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
23andMe Launches New Genetic Report on Osteoporosis
23andMe Special Committee Announces Exploration of Strategic Alternatives
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.